These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15239254)

  • 1. Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.
    Lersch C; Schmelz R; Erdmann J; Hollweck R; Schulte-Frohlinde E; Eckel F; Nader M; Schusdziarra V
    Hepatogastroenterology; 2004; 51(58):1099-103. PubMed ID: 15239254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
    Yang TS; Lin YC; Chen JS; Wang HM; Wang CH
    Cancer; 2000 Aug; 89(4):750-6. PubMed ID: 10951336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
    Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
    Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
    Kawata S; Yamasaki E; Nagase T; Inui Y; Ito N; Matsuda Y; Inada M; Tamura S; Noda S; Imai Y; Matsuzawa Y
    Br J Cancer; 2001 Apr; 84(7):886-91. PubMed ID: 11286466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
    Fuchs CS; Clark JW; Ryan DP; Kulke MH; Kim H; Earle CC; Vincitore M; Mayer RJ; Stuart KE
    Cancer; 2002 Jun; 94(12):3186-91. PubMed ID: 12115351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
    Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
    Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
    Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
    Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
    Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide therapy for advanced hepatocellular carcinoma.
    Slijkhuis WA; Stadheim L; Hassoun ZM; Nzeako UC; Kremers WK; Talwalkar JA; Gores GJ
    J Clin Gastroenterol; 2005 Apr; 39(4):333-8. PubMed ID: 15758629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
    Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
    Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.
    Guan Z; Wang Y; Maoleekoonpairoj S; Chen Z; Kim WS; Ratanatharathorn V; Reece WH; Kim TW; Lehnert M
    Br J Cancer; 2003 Nov; 89(10):1865-9. PubMed ID: 14612894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic treatment for hepatocellular carcinoma].
    Spangenberg HC; Zuber-Jerger I; Thimme R; Blum HE; Von Weizsäcker F
    Zentralbl Chir; 2003 Nov; 128(11):906-10. PubMed ID: 14669110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Somatostatin analogue (octreotide)].
    Sano K; Makuuchi M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.
    Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Markidou S; Panagiotakos D; Chrysohoou C; Bazinis A; Paraskevas E
    Hepatogastroenterology; 2002; 49(47):1245-50. PubMed ID: 12239914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas.
    Elpiner AK; Brodsky EM; Hazzah TN; Post GS
    Vet Comp Oncol; 2011 Dec; 9(4):260-8. PubMed ID: 22077406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.